Cargando…

Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status

BACKGROUND: Oncoprotein HCCR-1 functions as a negative regulator of the p53 and contributes breast tumorigenesis. The serum HCCR-1 assay is useful in diagnosing breast cancer and mice transgenic for HCCR developed breast cancers. But it is unknown how HCCR-1 contributes to human breast tumorigenesis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ha, Seon-Ah, Lee, Youn Soo, Shin, Seung Min, Kim, Hyun Kee, Kim, Sanghee, Namkoong, Hong, Kim, Hae Joo, Jung, Sang Min, Lee, Yu Sun, Chung, Yeun Jun, Jung, Sang Seol, Kim, Jin Woo
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672955/ https://www.ncbi.nlm.nih.gov/pubmed/19208263 http://dx.doi.org/10.1186/1471-2407-9-51

Ejemplares similares

Dual action of apolipoprotein E-interacting HCCR-1 oncoprotein and its implication for breast cancer and obesity
por: Ha, Seon-Ah, et al.
Publicado: (2009)

Transdifferentiation-inducing HCCR-1 oncogene
por: Ha, Seon-Ah, et al.
Publicado: (2010)

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
por: Jung, Jaehag, et al.
Publicado: (2017)

TCF/β-catenin plays an important role in HCCR-1 oncogene expression
por: Cho, Goang-Won, et al.
Publicado: (2009)

HCCR-1, a novel oncogene, encodes a mitochondrial outer membrane protein and suppresses the UVC-induced apoptosis
por: Cho, Goang-Won, et al.
Publicado: (2007)

ODP539 AIPB is a Biomarker for ER+/PR+/Her2- Breast Cancers
por: Cubbedge, Chandler, et al.
Publicado: (2022)

HCCR-1 for detecting small hepatocellular carcinoma latent in a cirrhotic liver: a prospective cohort study
por: Jirun, Peng, et al.
Publicado: (2012)

Serial Serum HER2 Measurements for the Detection of Breast Cancer Recurrence in HER2-Positive Patients
por: Ha, June-Hyung, et al.
Publicado: (2014)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
por: Chen, Chih-Jung, et al.
Publicado: (2022)

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022)

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ryu, Ho Hyun, et al.
Publicado: (2021)

Combined Analysis of AFP and HCCR-1 as an Useful Serological Marker for Small Hepatocellular Carcinoma: A Prospective Cohort Study
por: Zhang, Guoxin, et al.
Publicado: (2012)

The Association between ER, PR, HER2, and ER−/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database
por: Shao, Hong Yu, et al.
Publicado: (2023)

Clinical Utility of Alpha Fetoprotein and HCCR-1, Alone or in Combination, in Patients with Chronic Hepatitis, Liver Cirrhosis and Hepatocellular Carcinoma
por: Jirun, Peng, et al.
Publicado: (2011)

Prognostic Significance of HER2 Gene Amplification According to Stage of Breast Cancer
por: Kim, Yong-Seok, et al.
Publicado: (2008)

Calcitriol Inhibits Cervical Cancer Cell Proliferation Through Downregulation of HCCR1 Expression
por: Wang, Guoqing, et al.
Publicado: (2015)

Association of EGFR mutations in second primary lung cancer and HER2 expression in breast cancer survivors
por: Jang, Yoon Jung, et al.
Publicado: (2021)

Association between Acquired Uniparental Disomy and Homozygous Mutations and HER2/ER/PR Status in Breast Cancer
por: Tuna, Musaffe, et al.
Publicado: (2010)

The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes
por: Parise, Carol A., et al.
Publicado: (2015)

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67
por: Xu, Junnan, et al.
Publicado: (2018)

Machine Learning Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy for ER+HER2- Breast Cancer: Integrating Tumoral and Peritumoral MRI Radiomic Features
por: Park, Jiwoo, et al.
Publicado: (2023)

αB-Crystallin is a Novel Oncoprotein Associated with Poor Prognosis in Breast Cancer
por: Kim, Hae Sung, et al.
Publicado: (2011)

Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer
por: Shukla, Shailaja, et al.
Publicado: (2016)

Comparison of Her2/Neu Oncoprotein in Serum and Tissue Samples in Women with Breast Cancer
por: Pokhrel, Rakesh, et al.
Publicado: (2022)

Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
por: Seo, An Na, et al.
Publicado: (2016)

Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium
por: Howat, William J, et al.
Publicado: (2014)

Genetic and clinical landscape of ER + /PR- breast cancer in China
por: Dai, Danian, et al.
Publicado: (2023)

Clinical curative effect of neoadjuvant chemotherapy combined with immunotherapy and its impact on immunological function and the expression of ER, PR, HER-2 & SATB1 in HER-2-Positive breast cancer patients
por: Chen, Zhi, et al.
Publicado: (2022)

Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer
por: Bauer, Katrina, et al.
Publicado: (2010)

Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study
por: Hussein, Israa A, et al.
Publicado: (2020)

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (−) Breast Cancer
por: Du, Feng, et al.
Publicado: (2022)

Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance
por: Hu, Xueyang, et al.
Publicado: (2023)

STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers
por: Kim, Jae-Sung, et al.
Publicado: (2016)

The reality in the follow-up of breast cancer survivors: survey of Korean Breast Cancer Society
por: Kim, Ku Sang, et al.
Publicado: (2015)

An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER(−)/PR(−)/Her2(−) Human Breast Cancer Cells
por: Novikov, Olga, et al.
Publicado: (2016)

Deep learned tissue “fingerprints” classify breast cancers by ER/PR/Her2 status from H&E images
por: Rawat, Rishi R., et al.
Publicado: (2020)

BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma
por: Kumar, Mohit, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dbvf0sgooo4ggs10hvc3h23jnb